BGP replies to CEN deal cancelation

Bioglan (LSE:BGP) responded to Tuesday's news that CeNeS (LSE:CEN) was canceling an agreement with BGP to develop a sublingual opiate spray product to treat pain. CEN alleged that BGP had failed to co...